Esperion Therapeutics, Inc. (ESPR)Healthcare | Drug Manufacturers - Specialty & Generic | Ann Arbor, United States | NasdaqGM
2.04 USD
-0.01
(-0.488%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 2.05 +0.01 (0.490%) ⇧ (April 17, 2026, 8 p.m. EDT) Short-term: ★★★★☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:43 p.m. EDT
ESPR is flying under the radar on upside potential, with speculators aggressively buying calls while largely ignoring the downside in the immediate future (next 1-2 months). The near-term rating is high because the put volume is practically absent compared to the call gamma, suggesting a 'buy the dip' sentiment among chartists. However, the weak fundamentals (neg earnings), massive discount to the $7 analyst mean target, and lack of cash yield make it a long-term hold rather than a generational buy. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.185349 |
| AutoETS | 0.187050 |
| AutoARIMA | 0.187051 |
| AutoTheta | 0.233307 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 121.19 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.268 |
| Excess Kurtosis | -1.03 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 1.939 |
| Market Cap | 525,105,952 |
| Forward P/E | 6.95 |
| Beta | 1.17 |
| Profit Margins | -5.63% |
| Website | https://www.esperion.com |
As of April 18, 2026, 11:43 p.m. EDT: Options flow shows significant bullish positioning in out-of-the-money (OTM) calls for the near term (May/June 2026), with notable Open Interest (OI) at strikes above the current price ($2.04-$2.50) and deep OTM strikes ($3.00-$4.50) indicating a directional tesla toward upside. Conversely, the short-term put market (May/June 2026) displays extremely low positioning (OI <1M vs Calls >40k), suggesting minimal hedging or downside fear from speculators on immediate asset price. However, the longer-term horizon (2027+) shows increasing put OI, hinting at a divergence where traders are neutral on the near-term momentum but assign more weight to potential downside risks as expiration dates recede.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.4000001 |
| Address1 | 3,891 Ranchero Drive |
| Address2 | Suite 150 |
| All Time High | 120.96 |
| All Time Low | 0.69 |
| Ask | 2.08 |
| Ask Size | 8 |
| Audit Risk | 7 |
| Average Analyst Rating | 2.1 - Buy |
| Average Daily Volume10 Day | 8,734,740 |
| Average Daily Volume3 Month | 5,382,290 |
| Average Volume | 5,382,290 |
| Average Volume10Days | 8,734,740 |
| Beta | 1.172 |
| Bid | 2.03 |
| Bid Size | 1 |
| Board Risk | 6 |
| Book Value | -1.231 |
| City | Ann Arbor |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.04 |
| Current Ratio | 1.538 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 2.145 |
| Day Low | 2.015 |
| Display Name | Esperion Therapeutics |
| Earnings Call Timestamp End | 1,773,144,000 |
| Earnings Call Timestamp Start | 1,773,144,000 |
| Earnings Timestamp | 1,773,145,800 |
| Earnings Timestamp End | 1,777,984,200 |
| Earnings Timestamp Start | 1,777,984,200 |
| Ebitda | 60,378,000 |
| Ebitda Margins | 0.14977 |
| Enterprise To Ebitda | 14.973 |
| Enterprise To Revenue | 2.243 |
| Enterprise Value | 904,041,408 |
| Eps Current Year | 0.01333 |
| Eps Forward | 0.29333 |
| Eps Trailing Twelve Months | -0.11 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.8302 |
| Fifty Day Average Change | -0.7902 |
| Fifty Day Average Change Percent | -0.27920288 |
| Fifty Two Week Change Percent | 140.00002 |
| Fifty Two Week High | 4.18 |
| Fifty Two Week High Change | -2.1399999 |
| Fifty Two Week High Change Percent | -0.5119617 |
| Fifty Two Week Low | 0.69 |
| Fifty Two Week Low Change | 1.3499999 |
| Fifty Two Week Low Change Percent | 1.9565216 |
| Fifty Two Week Range | 0.69 - 4.18 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,372,253,400,000 |
| Float Shares | 254,560,822 |
| Forward Eps | 0.29333 |
| Forward P E | 6.954624 |
| Free Cashflow | -52,594,876 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 294 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.56075 |
| Gross Profits | 226,059,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00682 |
| Held Percent Institutions | 0.60933 |
| Implied Shares Outstanding | 257,404,876 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. |
| Long Name | Esperion Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 525,105,952 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_28236 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -22,682,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 525,105,947 |
| Number Of Analyst Opinions | 7 |
| Open | 2.11 |
| Operating Cashflow | -13,093,000 |
| Operating Margins | 0.506 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 734 887 3903 |
| Post Market Change | 0.00999999 |
| Post Market Change Percent | 0.49019563 |
| Post Market Price | 2.05 |
| Post Market Time | 1,776,470,400 |
| Previous Close | 2.05 |
| Price Eps Current Year | 153.03825 |
| Price Hint | 4 |
| Price To Book | -1.6571894 |
| Price To Sales Trailing12 Months | 1.302556 |
| Profit Margins | -0.05626 |
| Quick Ratio | 1.024 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.14286 |
| Region | US |
| Regular Market Change | -0.00999999 |
| Regular Market Change Percent | -0.487804 |
| Regular Market Day High | 2.145 |
| Regular Market Day Low | 2.015 |
| Regular Market Day Range | 2.015 - 2.145 |
| Regular Market Open | 2.11 |
| Regular Market Previous Close | 2.05 |
| Regular Market Price | 2.04 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 6,585,563 |
| Return On Assets | 0.09305 |
| Revenue Growth | 1.437 |
| Revenue Per Share | 1.939 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 257,404,876 |
| Shares Percent Shares Out | 0.129 |
| Shares Short | 33,129,776 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 33,525,831 |
| Short Name | Esperion Therapeutics, Inc. |
| Short Percent Of Float | 0.1295 |
| Short Ratio | 5.86 |
| Source Interval | 15 |
| State | MI |
| Symbol | ESPR |
| Target High Price | 16.0 |
| Target Low Price | 1.77998 |
| Target Mean Price | 6.99143 |
| Target Median Price | 5.16 |
| Total Cash | 167,852,000 |
| Total Cash Per Share | 0.654 |
| Total Debt | 548,000,000 |
| Total Revenue | 403,135,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.11 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.74995 |
| Two Hundred Day Average Change | -0.70995 |
| Two Hundred Day Average Change Percent | -0.25816834 |
| Type Disp | Equity |
| Volume | 6,585,563 |
| Website | https://www.esperion.com |
| Zip | 48,108 |